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Abstract The fatal toxicity index (FTI) is the absolute num-
ber of fatal poisonings caused by a particular drug divided by
its consumption figure. Consequently, it is a useful measure in
evaluating toxicity of the drug and its relevance in fatal poi-
sonings. In this study, we assessed the FTI of medicinal drugs
in 3 years (2005, 2009, and 2013) in Finland. As the measure
of drug consumption, we used the number of defined daily
doses (DDD) per population in each year. There were 70 me-
dicinal drugs in Finland for which the mean FTI expressed as
the number of deaths per million DDD over the three study
years was higher or equal to 0.1. The Anatomical Therapeutic
Chemical (ATC) classification system was used for the clas-
sification of the active ingredients of medicinal drugs accord-
ing to the organ or system which they act on. Of these 70
drugs, 55 drugs (78.6 %) acted on the nervous system (denot-
ed by ATC code N), 11 (15.7 %) on the cardiovascular system
(C), three (4.3 %) on the alimentary tract and metabolism (A),
and one (1.4 %) on the musculoskeletal system (M). The ner-
vous system drugs consisted of 20 psycholeptics, (ATC code
N05), 20 psychoanaleptics (N06), eight analgesics (N02), six
antiepileptics (N03), and one other nervous system drug
(N07). The highest individual FTIs were associated with the
opioids methadone, dextropropoxyphene, oxycodone, trama-
dol, and morphine; the antipsychotics levomepromazine and
chlorprothixene; and the antidepressants doxepin, amitripty-
line, trimipramine, and bupropion. Buprenorphine was not
included in the study, because most of the fatal buprenorphine
poisonings were due to smuggled tablets. A clearly increasing
trend in FTI was observed with pregabalin and possibly with
bupropion, both drugs emerging as abused substances.
Keywords FTI . Fatal poisonings . Drug sales . Forensic
toxicology . Post-mortem
Introduction
Statistics on drug-related deaths are of special interest not only
to clinical and forensic scientists but also to drug safety au-
thorities and policymakers. This is due to the fact that post-
mortem toxicology using sophisticated analytical technology
can produce more solid information on the role of illicit and
prescription drugs in poisonings than is obtained from patients
within the healthcare system. Comprehensive drug screening,
unequivocal identification, and quantitative analysis are an
essential part of the performance of post-mortem toxicology
laboratories, unlike hospital laboratories that usually rely on a
series of rapid immunoassay methods and thus only produce
tentative identification [1, 2]. Yet the agents involved in fatal
and non-fatal poisonings are largely similar [3]. Information
about the type and prevalence of drugs causing fatal poison-
ings are available from general registers maintained by the
national central statistical offices or from special registers,
such as those maintained by forensic institutions [4].
In addition to the absolute numbers of fatal poisonings
caused by particular drugs, consumption figures of drugs are
useful in evaluating their relevance in fatal poisonings. A
practical measure of relative drug toxicity is the fatal toxicity
index (FTI), which is calculated by relating the number of
deaths associated with a given drug to the number of prescrip-
tions for that drug over the same period and area [5–7]. For
illicit drugs, fatal toxicity can be evaluated by relating the
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number of associated deaths to measures of availability such
as seizures by law enforcement agencies [8]. Several recent
studies have been published addressing the FTI for various
classes of prescription drugs, such as antidepressants [9–11],
sedative-hypnotic drugs [12], carisoprodol [13], and metha-
done [14, 15]. Drug consumption has been expressed as the
number of prescriptions, kilograms, or defined daily doses
(DDD) dispensed. The DDD is the assumed average mainte-
nance dose per day for a drug used for its main indication in
adults also including the over-the-counter drugs, and thus the
number of DDD is a particularly useful measure of drug con-
sumption [16]. As fatal poisonings more often involve several
drugs instead of a single substance, deaths can be classified by
all drug findings, by all drugs implicated in the death, or by the
most important finding [14]. In Finland, the forensic patholo-
gist in charge of post-mortem cause-of-death investigation
needs to define in the death certificate the most important drug
finding of a fatal poisoning.
FTI as its many variants has proved to be a feasible tool for
assessing the relative toxicity of drugs in overdose. However,
the published studies have focused on specific drug catego-
ries, especially antidepressants, and have been based on vari-
ous research methods within different medicolegal systems.
There are no studies available aiming to establish the FTI for a
multiplicity of drugs and compare the changes between years,
using one comprehensive source of homogeneous data and
one study setting.
Our objective was to compare the prevalence of medicinal
drugs in major therapeutic categories in fatal poisonings relat-
ed to their consumption in Finland between three separate
years over a 9-year period: 2005, 2009, and 2013. The high
post-mortem toxicology rate and comprehensive-accredited
laboratory investigation produce extensive data on fatal poi-
sonings. As a slightly different array of medicines was on sale
each study year, we concentrate on those substances repeated-
ly implicated in fatal poisonings.
Materials and methods
The laboratory post-mortem database included a forensic pa-
thologist’s referral, laboratory analysis results, and informa-
tion from the death certificate issued by a forensic pathologist.
The referral contained background information from the po-
lice, such as a brief description of the circumstances of death,
known medications, and the main autopsy findings. The ana-
lytical data contained analysis results for alcohols, medicines,
and drugs of abuse and occasionally for other substances.
Information from the final death certificate included the age
and gender of the deceased, the cause of death with contrib-
uting factors according to the International Classification of
Diseases (ICD-10), and the manner of death according to the
World Health Organization. The manner of death in fatal
poisonings was accident, suicide, or unknown. In medicinal
drug poisonings, the principal drug finding indicated in the
death certificate was used as the basis to classify a fatal poi-
soning case. Due to the structure of the death certificate, the
present results are based on this most important single drug
finding in each case instead of all drugs implicated in the
death.
Drug consumption data, including hospital consumption,
were obtained from the Finnish Medicines Agency
(FIMEA), expressed as defined daily doses (DDD) per 1000
inhabitants per day (DDD/1000 inh/day). Data on fatal poi-
sonings were obtained from the laboratory post-mortem data-
base. The FTI was calculated by dividing the number of fatal
poisonings attributed to a certain drug by the consumption of
the drug over the same period. For example, there were six
fatal metoprolol poisonings in Finland during 2005 (0.11 poi-
sonings per 100,000 inhabitants), and the consumption of
metoprolol in 2005, measured as the number of DDD in the
whole population, was 44,274,057. This resulted in an FTI of
0.14 deaths per million DDD for metoprolol. Only those drugs
were included for which at least one fatal poisoning was re-
corded in at least two of the three study years. Drugs with
considerable illicit trafficking were omitted from the study
as the consumption of these drugs could not be assessed using
the present method.
The FTI for each studied drug was calculated both for the
individual study years (2005, 2009, and 2013) and as a sum of
all three years.
Results
The number of post-mortem toxicology cases investigated in
Finland in years 2005, 2009, and 2013 was 6210, 6892, and
6568, respectively, and these numbers represented 13.0, 13.8,
and 12.8 % of all deaths in each year, respectively. The num-
ber of fatal drug poisonings (illegal and medicinal) was 501,
636, and 476, respectively.
Table 1 shows the mean FTIs expressed as the number of
deaths per million DDD over the three study years for those 70
medicinal drugs in the descending order for which the FTI is
higher or equal to 0.1. Each fatal poisoning was categorized
by the most important drug finding associated with the death
as stated by the forensic pathologist in the death certificate.
The Anatomical Therapeutic Chemical (ATC) classification
system was used for the classification of the active ingredients
of medicinal drugs according to the organ or system which
they act on. Of the 70 drugs, 55 drugs (78.6 %) acted on the
nervous system (N), 11 (15.7 %) on the cardiovascular system
(C), three (4.3 %) on the alimentary tract and metabolism (A),
and one (1.4 %) on the musculoskeletal system (M). The ner-
vous system drugs consisted of 20 psycholeptics (N05), 20
1210 Int J Legal Med (2016) 130:1209–1216
Table 1 Mean fatal toxicity index (FTI) and manner of death from 2005, 2009, and 2013 in Finland for 70 medicinal drugs according to descending
order of FTI
Total deaths Total sales Mean FTI Manner of death
DDD (Deaths/106 DDD) Suicide (%) Unknown (%) Accident (%)
N07BC02 Methadone 32 750,333 42.65 0 6 94
N02AC04 Dextropropoxyphene 27 847,894 31.84 56 4 37
N05AA02 Levomepromazine 79 3,604,456 21.92 48 15 37
N06AA12 Doxepin 61 4,359,963 13.99 57 25 18
N05AF03 Chlorprothixene 22 3,095,410 7.11 41 32 27
N02AA05 Oxycodone 51 7,542,630 6.76 35 12 51
N06AA09 Amitriptyline 106 16,216,626 6.54 58 18 25
N06AA06 Trimipramine 7 1,107,592 6.32 43 14 43
N02AX02 Tramadol 96 16,886,539 5.69 39 15 47
N02AA01 Morphine 8 1,527,852 5.24 38 0 63
N06AX12 Bupropion 14 3,210,318 4.36 93 0 7
N05AL01 Sulpiride 2 428,758 4.66 0 100 0
N06AA04 Clomipramine 6 1,385,030 4.33 17 67 17
C07AA05 Propranolol 44 11,491,298 3.83 91 5 5
N05AH04 Quetiapine 56 22,267,205 2.51 86 9 5
N06AX05 Trazodone 2 820,214 2.44 100 0 0
N02AB03 Fentanyl 16 7,799,630 2.05 0 13 88
N05AA01 Chlorpromazine 3 1,513,916 1.98 33 33 33
N02AA59 Codeinea 113 57,346,321 1.97 38 20 42
N03AX16 Pregabalin 39 20,299,971 1.92 18 23 59
N06AX18 Reboxetine 1 524,657 1.91 0 0 100
N06AB08 Fluvoxamine 4 2,277,310 1.76 100 0 0
N06AA10 Nortriptyline 3 1,747,041 1.72 33 33 33
N06AX03 Mianserin 6 3,718,824 1.61 17 0 83
N05AH02 Clozapine 20 12,673,159 1.58 45 20 35
N06AX16 Venlafaxine 51 40,567,623 1.26 63 20 18
N05BA12 Alprazolam 41 40,340,908 1.02 41 2 56
N06AB05 Paroxetine 16 17,126,500 0.93 25 44 31
N06AG02 Moclobemide 3 3,274,090 0.92 33 67 0
N03AX12 Gabapentin 6 6,579,026 0.91 33 50 17
N03AF01 Carbamazepine 10 11,645,023 0.86 50 30 20
N05AH03 Olanzapine 24 30,079,094 0.80 63 25 13
C01AA05 Digoxin 20 27,148,383 0.74 50 10 20
C01BC04 Flecainide 5 6,874,115 0.73 80 0 20
N05BB01 Hydroxyzine 6 8,682,932 0.69 50 17 33
C08DA01 Verapamil 4 5,806,157 0.69 100 0 0
C07AB04 Acebutolol 3 4,629,967 0.65 100 0 0
N06AX11 Mirtazapine 28 45,645,484 0.61 57 14 29
N03AX09 Lamotrigine 5 9,036,037 0.55 100 0 0
C02CA01 Prazosin 1 1,932,456 0.52 100 0 0
N05CD07 Temazepam 45 87,120,115 0.52 71 11 16
N05CF01 Zopiclone 71 141,258,189 0.50 66 14 20
N06AX21 Duloxetine 5 10,130,365 0.49 60 40 0
N03AE01 Clonazepam 2 5,531,926 0.36 0 50 50
N02BA Salicylate 5 14,196,273 0.35 40 40 20
N06BC01 Caffeine 1 2,840,800 0.35 100 0 0
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psychoanaleptics (N06), eight analgesics (N02), six antiepi-
leptics (N03), and one other nervous system drug (N07).
Additionally, the percentages of suicide, unknown manner
of death, and accident for each drug are illustrated in Table 1.
Table 2 shows the FTIs of 56 medicinal drugs in 2005,
2009, and 2013 divided into major pharmacological catego-
ries and, within categories, arranged according to the descend-
ing order of FTI in 2013. As only those drugs were included
for which at least one fatal poisoning was recorded in at least
two of the three study years, a total of 40 different drugs
associated with less poisoning cases were omitted from the
study. Buprenorphine was not included in the study due to a
high volume of illicit trafficking.
Discussion
Central nervous system drugs, especially antipsychotics
(N05A), antidepressants (N06A), and opioid analgesics
(N02A), comprise the majority of the drugs with a high FTI.
Table 1 shows that 21 drugs have an average FTI ≥1.0 deaths
per million DDD based on six or more deaths over the three
study years, which can be attributed to especially high toxic-
ity. The only cardiac drug meeting these criteria is the adren-
ergic beta-blocking drug propranolol that, interestingly, is also
prescribed for psychiatric conditions, e.g., against stage fright.
As seen in Table 1, the manner of death is unknown in unex-
pectedly many cases, which may reflect the fact that forensic
pathologists hesitate to define an overdose death as suicide
without irrefutable evidence.
Among antipsychotics, our data shows that the major toxic
drugs are levomepromazine, chlorprothixene, quetiapine, and
clozapine. The high toxicity and the high rate of suicide
among the users of the older antipsychotics are quite well
known, and these factors probably explain some of our results.
Unfortunately, very little data on FTIs of antipsychotic drugs
is available in the literature for the comparison of our results
[17]. The atypical antipsychotics quetiapine and olanzapine
are to be followed carefully as there is evidence of diversion,
misuse, and even dependency syndrome following a marked
increase in prescribing of these agents [18]. Recently, the off-
label prescribing of quetiapine to treat anxiety and insomnia of
Table 1 (continued)
Total deaths Total sales Mean FTI Manner of death
DDD (Deaths/106 DDD) Suicide (%) Unknown (%) Accident (%)
N05CF02 Zolpidem 11 38,111,177 0.29 82 0 18
M03BX02 Tizanidine 3 10,875,377 0.28 67 0 33
N05AF05 Zuclopenthixol 1 3,955,418 0.25 0 100 0
N05AD01 Haloperidol 1 4,074,436 0.25 100 0 0
A10A Insulins and analogs 39 159,966,644 0.24 74 18 5
N05AB03 Perphenazine 1 4,205,043 0.24 100 0 0
C08DB01 Diltiazem 3 13,269,634 0.23 67 33 0
N02BE01 Paracetamol 29 133,401,723 0.22 34 21 41
N06AB04 Citalopram and escitalopram 31 150,329,960 0.21 61 16 23
N03AG01 Valproic acid 4 20,031,058 0.20 100 0 0
N06AB06 Sertraline 7 35,054,950 0.20 29 14 57
A10BA02 Metformin 32 170,671,697 0.19 28 34 38
N05BA02 Chlordiazepoxide 1 5,785,137 0.17 0 100 0
N05AN Lithium 1 6,055,199 0.17 0 0 100
A03FA01 Metoclopramide 1 6,103,943 0.16 0 0 100
C07AA07 Sotalol 1 6,140,399 0.16 100 0 0
N05CD02 Nitrazepam 1 6,183,677 0.16 100 0 0
N06BA04 Methylphenidate 1 6,423,566 0.16 0 100 0
N05AX08 Risperidone 2 13,623,381 0.15 100 0 0
N05BA04 Oxazepam 6 41,209,268 0.15 50 33 17
N06AB03 Fluoxetine 4 29,186,025 0.14 50 25 25
C07AB03 Atenolol 3 24,143,785 0.12 67 0 33
C07AB02 Metoprolol 12 118,750,034 0.10 75 8 17
C01DA02 Glyceryl trinitrate 1 9,982,046 0.10 100 0 0
a Excluding codeine combinations in cough medicines
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Table 2 Fatal toxicity indices (FTI) in 2005, 2009, and 2013 in Finland for 56 medicinal drugs in descending order of FTI in 2013
ATC code 2005 2009 2013


























A10A Insulins and analogs 12 0.23 41.63 0.29 12 0.22 55.90 0.21 15 0.28 62.44 0.24
A10BA02 Metformin 7 0.13 35.43 0.20 17 0.32 62.91 0.27 8 0.15 72.33 0.11
Cardiac drugs (C01A, C08)
C08DA01 Verapamil 1 0.02 2.38 0.42 1 0.02 1.86 0.54 2 0.04 1.57 1.27
C08DB01 Diltiazem 1 0.02 6.52 0.15 0.00 4.14 0.00 2 0.04 2.61 0.77
C01AA05 Digoxin 9 0.17 11.45 0.79 6 0.11 8.67 0.69 5 0.09 7.02 0.71
C08CA01 Amlodipine 0.00 45.18 0.00 4 0.07 68.25 0.06 9 0.17 92.34 0.10
C01BC04 Flecainide 1 0.02 1.80 0.55 4 0.07 2.29 1.75 0.00 2.79 0.00
Beta-blocking agents (C07)
C07AA05 Propranolol 14 0.27 3.66 3.82 23 0.43 3.85 5.98 7 0.13 3.98 1.76
C07AB02 Metoprolol 6 0.11 44.27 0.14 5 0.09 40.47 0.12 1 0.02 34.00 0.03
C07AB07 Bisoprolol 3 0.06 51.06 0.06 3 0.06 68.93 0.04 1 0.02 80.38 0.01
C07AB03 Atenolol 1 0.02 10.90 0.09 2 0.04 7.66 0.26 0.00 5.59 0.00
Antiinflammatory drugs and muscle relaxants (M01, M03)
M03BX02 Tizanidine 0.00 3.20 0.00 2 0.04 3.65 0.55 1 0.02 4.02 0.25
M01AE01 Ibuprofen 1 0.02 78.36 0.01 1 0.02 94.89 0.01 0.00 99.47 0.00
Analgesics (N02)
N02AA05 Oxycodone 9 0.17 1.84 4.89 20 0.37 2.64 7.58 22 0.40 3.06 7.18
N02AX02 Tramadol 21 0.40 5.37 3.91 35 0.65 5.61 6.24 40 0.73 5.91 6.77
N02AB03 Fentanyl 0.00 2.92 0.00 6 0.11 2.72 2.21 10 0.18 2.17 4.61
N02AA59 Codeinea 45 0.86 18.17 2.48 46 0.86 20.12 2.29 22 0.40 19.06 1.15
N02BE01 Paracetamol 5 0.10 28.97 0.17 7 0.13 46.10 0.15 17 0.31 58.34 0.29
N02AA01 Morphine 1 0.02 0.38 2.61 7 0.13 0.53 13.27 0.00 0.62 0.00
N02BA Salicylate 1 0.02 4 0.07 9.08 0.44 0.00 5.11 0.00
N02AC04 Dextropropoxyphene 13 0.25 0.63 20.54 13 0.24 0.21 60.50 1 0.02 0.00
Antiepileptics (N03)
N03AX16 Pregabalin 1 0.02 1.84 0.54 12 0.22 7.79 1.54 26 0.48 10.66 2.44
N03AF01 Carbamazepine 6 0.11 4.35 1.38 3 0.06 3.83 0.78 1 0.02 3.46 0.29
N03AG01 Valproic acid 1 0.02 5.81 0.17 2 0.04 6.82 0.29 1 0.02 7.40 0.14
N03AX09 Lamotrigine 2 0.04 2.07 0.97 3 0.06 3.18 0.94 0.00 3.78 0.00
N03AX12 Gabapentin 1 0.02 1.92 0.52 5 0.09 1.88 2.67 0.00 2.79 0.00
Antipsychotics (N05A)
N05AA02 Levomepromazine 38 0.72 1.46 26.06 26 0.49 1.19 21.82 15 0.28 0.96 15.71
N05AF03 Chlorprothixene 11 0.21 1.32 8.31 3 0.06 1.02 2.95 8 0.15 0.76 10.58
N05AL01 Sulpiride 1 0.02 0.17 5.79 0.00 0.14 0.00 1 0.02 0.12 8.38
N05AH04 Quetiapine 11 0.21 4.01 2.74 25 0.47 7.87 3.18 20 0.37 10.39 1.93
N05AH02 Clozapine 5 0.10 3.74 1.34 7 0.13 4.34 1.61 8 0.15 4.60 1.74
N05AH03 Olanzapine 7 0.13 8.29 0.84 9 0.17 10.41 0.86 8 0.15 11.38 0.70
N05AA01 Chlorpromazine 2 0.04 0.75 2.67 1 0.02 0.55 1.83 0.00 0.22 0.00
Anxiolytics (N05B)
N05BB01 Hydroxyzine 0.00 2.67 0.00 3 0.06 2.79 1.07 3 0.06 3.22 0.93
N05BA12 Alprazolam 13 0.25 14.52 0.90 19 0.36 14.24 1.33 9 0.17 11.58 0.78
N05BA04 Oxazepam 1 0.02 14.75 0.07 0.00 14.16 0.00 5 0.09 12.30 0.41
Hypnotics and sedatives (N05C)
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drug addicts has been increasing markedly in Finland and
other countries [19].
Among antidepressants, the highest relative toxicity based
on our data is seen with doxepin, amitriptyline, trimipramine,
bupropion, clomipramine, mianserin, and venlafaxine. The
present study confirms the earlier findings that the FTIs for
the tricyclic antidepressants are significantly higher than those
for the selective serotonin reuptake inhibitors (SSRI), while
the other antidepressants fall in between [20–22]). Swedish
researchers reported FTI values based on DDD but considered
only fatal mono-intoxications due to one single drug in their
calculations, and consequently their FTI values were lower
than here [9]. Bupropion, a cathinone derivative, is currently
prescribed both for smoking cessation and depression. As in-
dicated in Table 2, the FTI of bupropion is drastically higher in
2013 compared to the two earlier study years. There are recent
reports in the literature concerning bupropion abuse [23], but
it is not yet known if the increase of FTI in our material is due
to emerging bupropion abuse or other reasons.
Among opioid analgesics, methadone, dextropropoxyphene,
oxycodone, tramadol, morphine, fentanyl, and codeine are the
drugs with the highest FTI. The strong opioids methadone,
oxycodone, morphine, and fentanyl involve much abuse
resulting in unintentional deaths, while the manner of death
for the weak opioids dextropropoxyphene, tramadol, and co-
deine is often more difficult to establish. Buprenorphine, one of
the most important drugs that had caused fatal poisonings in
Finland, is not included in the present study, because most of
the fatal buprenorphine poisonings were due to smuggled tab-
lets [24]. Methadone is predominantly used in opioid mainte-
nance treatment, and the drug is associated with a substantial
amount of abuse and diversion. However, the insignificance of
its illicit trafficking allows us to include methadone in this
study. The FTI of methadone, although showing large variation
between the study years, compares well with the essentially
similar OD4 score reported to be 20–63 in Victoria, Australia,
during 1990–2005 [15]. Dextropropoxyphene is one of the few
drugs that have been recalled from the market due to abuse and
Table 2 (continued)
ATC code 2005 2009 2013

























N05CD07 Temazepam 13 0.25 35.39 0.37 19 0.36 30.12 0.63 13 0.24 21.61 0.60
N05CF01 Zopiclone 30 0.57 51.54 0.58 29 0.54 49.18 0.59 12 0.22 40.53 0.30
N05CF02 Zolpidem 4 0.08 11.72 0.34 4 0.07 13.50 0.30 3 0.06 12.89 0.23
Antidepressants (N06A)
N06AA12 Doxepin 22 0.42 1.84 11.95 30 0.56 1.52 19.69 9 0.17 0.99 9.05
N06AX12 Bupropion 1 0.02 0.81 1.24 0.00 0.16 0.00 13 0.24 2.25 5.78
N06AA06 Trimipramine 4 0.08 0.56 7.19 2 0.04 0.31 6.40 1 0.02 0.24 4.19
N06AA09 Amitriptyline 46 0.88 4.74 9.71 39 0.73 5.45 7.16 21 0.39 6.03 3.48
N06AX16 Venlafaxine 11 0.21 8.15 1.35 24 0.45 13.73 1.75 16 0.29 18.68 0.86
N06AB05 Paroxetine 6 0.11 6.37 0.94 6 0.11 5.68 1.06 4 0.07 5.07 0.79
N06AX21 Duloxetine 0.00 0.23 0.00 1 0.02 4.73 0.21 4 0.07 5.17 0.77
N06AX11 Mirtazapine 9 0.17 12.10 0.74 16 0.30 16.29 0.98 3 0.06 17.25 0.17
N06AB06 Sertraline 3 0.06 9.69 0.31 2 0.04 11.80 0.17 2 0.04 13.57 0.15
N06AB04 Citalopram and
escitalopram
10 0.19 40.02 0.25 14 0.26 55.20 0.25 7 0.13 55.12 0.13
N06AB03 Fluoxetine 0.00 10.65 0.00 3 0.06 9.84 0.30 1 0.02 8.70 0.12
N06AA04 Clomipramine 3 0.06 0.52 5.79 3 0.06 0.45 6.68 0.00 0.42 0.00
N06AA10 Nortriptyline 1 0.02 0.33 3.07 2 0.04 0.63 3.20 0.00 0.80 0.00
N06AB08 Fluvoxamine 1 0.02 0.96 1.04 3 0.06 0.80 3.75 0.00 0.52 0.00
N06AG02 Moclobemide 2 0.04 1.29 1.56 1 0.02 1.11 0.90 0.00 0.88 0.00
N06AX03 Mianserin 3 0.06 1.57 1.91 3 0.06 1.23 2.44 0.00 0.92 0.00
Drugs used in addictive disorders (N07B)
N07BC02 Methadone 1 0.02 0.10 10.43 20 0.37 0.12 170.65 11 0.20 0.54 20.48
a Excluding codeine combinations in cough medicines
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excessive overdose deaths—only to be replaced by another
problematic drug, tramadol.
Two sedative drugs, pregabalin and alprazolam, stand out
in our study by having caused fatal poisonings especially in
combination with opioids. Pregabalin is used in the treatment
of neuropathic pain and epilepsy, as well as in generalized
anxiety disorder. The drug has a steadily increasing FTI dur-
ing the study years. This is obviously due to the fact that
pregabalin with high doses produces benzodiazepine-like ef-
fects and thus possesses considerable abuse potential as such
or as an opioid booster [25]. Alprazolam is the benzodiazepine
with a high abuse liability [26], and it shows the highest FTI of
all benzodiazepines in our material. Swedish researchers pub-
lished FTI values for sedative and hypnotic drugs based either
on fatal mono-intoxications or multi-drug intoxications [12].
The former values were understandably always lower than in
our study but the latter were fairly similar to ours, e.g., for
zopiclone (0.79), zolpidem (0.52), and alprazolam (0.52).
The changes observed in the number of fatal intoxications
caused by a certain drug in the study period mainly followed
the changes in the sales of the drug (Table 2). It could be
hypothesized that if the FTI for an individual drug remained
similar between the years, the result would represent an accu-
rate measure of the relative toxicity of this substance. Our data
roughly supports this hypothesis as the typical antipsychotics,
tricyclic antidepressants, and opioids rank steadily high,
followed by atypical antipsychotics and other antidepressants,
while sedative-hypnotics, anxiolytics, antiepileptics, and
SSRI drugs had somewhat lower FTIs. However, prescription
practices, abuse potential, and the patient’s perception of tox-
icity associated with a drug play a major role, and the FTI may
change in time as can be seen with pregabalin and possibly
with bupropion.
There are some limitations in this study. Most fatal poison-
ings are caused by multiple drugs taken simultaneously, while
the present results are based on the most important single drug
finding in each case. The contribution of other drugs present in
these poisoning cases could not be taken into account.
Occasionally, it can be challenging for the forensic pathologist
to point out a single substance as the underlying cause of
death. The number of cases attributed to certain drugs listed
in the tables is too low to draw statistically significant conclu-
sions. The fatal poisonings due to citalopram and escitalopram
could not be differentiated in the present material. Finally, the
sales figures of cough medicines (syrups) containing codeine
were not available to us.
Conclusions
Instead of simply calculating the absolute numbers of poison-
ing deaths, the FTI measures relative toxicity and ranks vari-
ous medicinal drugs according to their lethality. This
information helps forensic toxicologists and pathologists in
interpreting drug findings in the cause-of-death investigation.
In addition, policymakers can exploit the FTI in monitoring
the lethality of medicinal drugs in time and detect possible
trends that require intervention. The number of DDD is a
particularly useful measure of drug consumption, and these
figures are usually readily available. The present study has
determined the FTI for a larger set of different drugs than
has been reported earlier.
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